5-methyl-6-(3-nitrophenyl)-4,5-dihydro-2H-pyridazin-3-one | 36725-30-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-methyl-6-(3-nitrophenyl)-4,5-dihydro-2H-pyridazin-3-one
• 英文别名: 5-methyl-6-(3-nitro-phenyl)-4,5-dihydro-2H-pyridazin-3-one；4,5-dihydro-5-methyl-6-(m-nitrophenyl)-3-(2H)-pyridazinone；4,5-dihydro-5-methyl-6-(m-nitrophenyl)-3(2H)-pyridazinone；4,5-Dihydro-5-methyl-6-(m-nitrophenyl)-3-(2H)pyridazinon；4-methyl-3-(3-nitrophenyl)-4,5-dihydro-1H-pyridazin-6-one
• CAS: 36725-30-1
• 化学式: C₁₁H₁₁N₃O₃
• 分子量: 233.227
• InChiKey: DQVXIICCNCTEGA-UHFFFAOYSA-N

物化性质

• 熔点：
  191-194 °C
• 密度：
  1.42±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  87.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-methyl-6-(3-nitrophenyl)-4,5-dihydro-2H-pyridazin-3-one 在 盐酸 、 铁粉 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以79%的产率得到6-(3-aminophenyl)-5-methyl-4,5-dihydro-2H-pyridazin-3-one
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids:  A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents

  摘要：

  In this study, the synthesis and in vitro and in vivo pharmacological investigations of a new series of phthalazinone/pyridazinone hybrids with both PDE3 and PDE4 inhibitory activities are described. These compounds combine the pharmacophores of recently discovered 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one-type inhibitors of PDE4 and the well-known 2H-pyridazin-3-one-type PDE3 inhibitors such as the tetrahydrobenzimidazoles. Most of the synthesized compounds are pharmacologically spoken PDE3/PDE4 hybrids. All hybrids show potent PDE4 inhibitory activity (pIC(50) = 7.0-8.7), whereas the pIC(50) values for inhibition of PDE3 vary from 5.4 to 7.5. In general, analogues with a 5-methyl-4,5-dihydropyridazinone moiety exhibit the highest PDE3 inhibitory activities. The highest in vivo antiinflammatory activity is displayed by phthalazinones 43 and 44 showing, at a dose of 30 mumol/kg po, 46% inhibition of arachidonic acid (AA) induced mouse ear edema. No correlation was found between the in vitro PDE3 and/or PDE4 inhibitory activity and the in vivo antiinflammatory capacity after oral dosing.

  DOI：

  10.1021/jm030776l
• 作为产物：
  描述：

  2-溴-1-(3-硝基苯基)丙烷-1-酮 在 盐酸 、 sodium hydride 、 一水合肼 作用下， 以 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 10.0h， 生成 5-methyl-6-(3-nitrophenyl)-4,5-dihydro-2H-pyridazin-3-one
  参考文献：
  名称：

  Synthesis and Structure−Activity Relationships of cis-Tetrahydrophthalazinone/Pyridazinone Hybrids:  A Novel Series of Potent Dual PDE3/PDE4 Inhibitory Agents

  摘要：

  In this study, the synthesis and in vitro and in vivo pharmacological investigations of a new series of phthalazinone/pyridazinone hybrids with both PDE3 and PDE4 inhibitory activities are described. These compounds combine the pharmacophores of recently discovered 4a,5,8,8a-tetrahydro-2H-phthalazin-1-one-type inhibitors of PDE4 and the well-known 2H-pyridazin-3-one-type PDE3 inhibitors such as the tetrahydrobenzimidazoles. Most of the synthesized compounds are pharmacologically spoken PDE3/PDE4 hybrids. All hybrids show potent PDE4 inhibitory activity (pIC(50) = 7.0-8.7), whereas the pIC(50) values for inhibition of PDE3 vary from 5.4 to 7.5. In general, analogues with a 5-methyl-4,5-dihydropyridazinone moiety exhibit the highest PDE3 inhibitory activities. The highest in vivo antiinflammatory activity is displayed by phthalazinones 43 and 44 showing, at a dose of 30 mumol/kg po, 46% inhibition of arachidonic acid (AA) induced mouse ear edema. No correlation was found between the in vitro PDE3 and/or PDE4 inhibitory activity and the in vivo antiinflammatory capacity after oral dosing.

  DOI：

  10.1021/jm030776l

文献信息

• Hypotensive alkyl-3-[6-(aryl)-3-pyridazinyl]-carbazates
  申请人：American Cyanamid Company

  公开号：US04092311A1

  公开（公告）日：1978-05-30

  This disclosure describes novel alkyl 3-[6-(aryl)-3-pyridazinyl]-carbazates useful as hypotensive agents in mammals. SP CROSS REFERENCE TO RELATED APPLICATIONS This application is a continuation of our copending application Ser. No. 692,254, filed June 3, 1976 now abandoned, which in turn is a continuation-in-part of our abandoned application Ser. No. 552,024, filed Feb. 24, 1975 now abandoned.

  本公开描述了一种新的烷基3-[6-(芳基)-3-吡啶并嗪基]-氨基甲酸酯，可用作哺乳动物的降压剂。SP与相关申请的交叉引用 本申请是我们待决申请Ser. No. 692,254的延续申请，该待决申请于1976年6月3日提交，现已废弃，而该待决申请又是我们废弃申请Ser. No. 552,024的部分延续申请，该废弃申请于1975年2月24日提交，现已废弃。
• 6-Phenyl-1,2,4-triazolo[4,3-b]pyridazine hypotensive agents
  申请人：American Cyanamid Company

  公开号：US04112095A1

  公开（公告）日：1978-09-05

  This disclosure describes novel substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines useful as hypotensive agents.

  本公开说明了一种新型的取代的6-苯基-1,2,4-三唑并[4,3-b]吡啶嗪，可用作降压剂。
• Method for treating anxiety in mammals
  申请人：American Cyanamid Company

  公开号：US04117130A1

  公开（公告）日：1978-09-26

  This disclosure describes compositions of matter useful as anxiolytic agents and the method of meliorating anxiety in mammals therewith; the active ingredients of said compositions of matter being certain substituted 6-phenyl-1,2,4-triazolo[4,3-b]pyridazines or the pharmacologically acceptable acid-addition salts thereof.

  本文描述了作为抗焦虑剂有用的物质组成和利用其改善哺乳动物焦虑的方法；所述物质组成的活性成分是某些取代的6-苯基-1,2,4-三唑并[4,3-b]吡啶嗪或其药理学上可接受的酸盐加成物。
• US4092311A
  申请人：——

  公开号：US4092311A

  公开（公告）日：1978-05-30
• US4117130A
  申请人：——

  公开号：US4117130A

  公开（公告）日：1978-09-26